Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 19

Results For "UPI"

510 News Found

Lupin receives USFDA’s approval for Febuxostat Tablets
Drug Approval | January 19, 2024

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)


Lupin Life hosted Second Edition of Aptivate Champion Run for Kids
News | January 15, 2024

Lupin Life hosted Second Edition of Aptivate Champion Run for Kids

The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars


Lupin launches Varenicline Tablets in US
News | January 11, 2024

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb


Lupin launches second edition of Aptivate Champion Run for Kids
News | January 09, 2024

Lupin launches second edition of Aptivate Champion Run for Kids

Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run


Cupid receives 16.23 Cr order from Central Medical Services Society
News | January 09, 2024

Cupid receives 16.23 Cr order from Central Medical Services Society

The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively


Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Drug Approval | January 04, 2024

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US


Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.2%
Drug Approval | December 27, 2023

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis